CVRdatabase
Menu

Akasi Pharma ApS

Private limited companyCVR 45364577København NActive

Akasi Pharma ApS is a private limited company, based in København N, active in research and experimental development on natural sciences and engineering, founded in 2025. Equity was negative at the end of 2025 (−DKK 1.6m). The company is new and has been registered for 1 years. The latest net result (2025) was a loss of DKK 1.6m.

Follow
PDF reportCompare

Key figures · financial year 2025

RevenueDKK 1m
Net profit−DKK 1.6m
Equity−DKK 1.6m
Employees4latest month from CVR

What has changed

calculated from recorded figures and dates

Employees

  • 2 more employees than a year earlier: 4 (07/2026) against 2 (07/2025).

Management and owners, last 24 months

  • New in management: Walden Emil Bjørn-Yoshimoto (director, 29/01/2025) and Helena Safavi-Hemami (director, 29/01/2025).
  • New owners registered: Walden Holding ApS (29/01/2025), Sophie Holding ApS (17/10/2025) and Venimic LLC (17/10/2025) (+1).
  • No longer registered as owner: Venimic LLC (16/10/2025).

Registrations, last 24 months

  • 17/10/2025: Share capital changed from 40,000 DKK to 56,000 DKK

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2025–2025 · amounts in DKK thousand
Financial figures for Akasi Pharma ApS
2025Change
Revenue1,027–
Gross profit−714–
Operating profit (EBIT)−1,623–
Profit before tax−1,627–
Net profit−1,627–
Total assets2,486–
Equity−1,571–
Liabilities4,057–
Cash and cash equivalents2,434–

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report.

Download the figures as CSV · free with an account, amounts in whole DKK

Signals from the financial statements

calculated from the 2025 figures

  • Negative equity

    Equity was −DKK 1.6m at the end of 2025.

    How is this calculated?

    Equity in the latest annual report is below zero.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

1 financial years
Annual reports for Akasi Pharma ApS
Financial yearPeriodPublishedFigures forDocuments
202529/01/2025 – 31/12/202512/03/2026The companyPDF not statedXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
0123403/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/26
Employees

Position in the industry

431 companies in the database

Comparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.

Gross profit−DKK 714kNo. 310 of 421
Better than 26% of the companies in the industry
Equity−DKK 1.6mNo. 355 of 431
Better than 18% of the companies in the industry
Number of employees4No. 224 of 431
Better than 48% of the companies in the industry

Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.

DKK 100kDKK 2.5mDKK 63.4mDKK 1.6bnDKK 13.7bn
Distribution of gross profit for 250 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with fewer than 20 employees69,967 companies in the comparison
No. 68,461of 69,742
Better than 2%
No. 67,904of 69,964
Better than 3%
Same industry and fewer than 20 employees329 companies in the comparison
No. 233of 323
Better than 28%
No. 265of 329
Better than 20%
Companies that are founded within the last five years16,662 companies in the comparison
No. 16,213of 16,614
Better than 2%
No. 16,111of 16,661
Better than 3%
All companies of type ApS66,508 companies in the comparison
No. 65,390of 66,379
Better than 1%
No. 64,439of 66,505
Better than 3%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Research and experimental development on natural sciences and engineering
Gross profit
  1. Akasi Pharma ApS−DKK 714k
  2. Carlsberg A/SDKK 40.2bn
  3. Zealand Pharma A/SDKK 9.2bn
Net profit
  1. Akasi Pharma ApS−DKK 1.6m
  2. Carlsberg A/SDKK 7bn
  3. Zealand Pharma A/SDKK 6.5bn
Equity
  1. Akasi Pharma ApS−DKK 1.6m
  2. Carlsberg A/SDKK 30.7bn
  3. Zealand Pharma A/SDKK 14.8bn
Employees
  1. Akasi Pharma ApS4
  2. Carlsberg A/S107
  3. Zealand Pharma A/S569

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • Walden Holding ApS50%
  • Sophie Holding ApS10%
  • Venimic LLC25%
Akasi Pharma ApS

Management

2 active registrations

Executive management

Executive management at Akasi Pharma ApS
NameRoleAppointed
Walden Emil Bjørn-YoshimotoDirector29/01/2025
Helena Safavi-HemamiDirector29/01/2025
Founders
Walden Holding ApS, Venimic LLC

Signing rule: Selskabet tegnes af en direktør eller den samlede direktion.

Address and production units

1 active production units

Ole Maaløes Vej 3
2200 København N

København Municipality · Postcode 2200

Other companies at the address (8)

  • BII Holdings A/SOther financial service activities n.e.c.
  • Skape Bio ApSResearch and experimental development on natural sciences and engineering
  • Agrobiomics ApSResearch and experimental development on natural sciences and engineering
  • Tetrakit Technologies ApSResearch and experimental development on natural sciences and engineering
  • BioColor ApSResearch and experimental development on natural sciences and engineering
Production units
Production unitAddressEmployeesP number
Akasi Pharma ApSOle Maaløes Vej 3, 2200 København N41031031903

Purpose

Selskabets formål er at udføre forskning, udvikling, produktion og handel med lægemidler, samt at udøve enhver aktivitet, der har direkte eller indirekte forbindelse hermed.

The purpose is quoted from the register in Danish.

Changes year by year

10 registered events
20261 changeaccounts 1
  • Annual report for 2025 published
20259 changescapital 1 · ownership 5 · founded 1 · management 2
  • Share capital changed from 40,000 DKK to 56,000 DKK
  • Sophie Holding ApS registered as owner (10%)
  • Venimic LLC registered as owner (25%)
  • Venimic LLC is no longer registered as owner
  • Registered as Akasi Pharma ApS
  • Walden Emil Bjørn-Yoshimoto appointed director
  • Helena Safavi-Hemami appointed director
  • Venimic LLC registered as owner (33.33%)
  • Walden Holding ApS registered as owner (50%)

Related companies

Same industry in København

See all →

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.

View in CVRReport a correction